[Field trial of the early detection in patients with ovarian cancer].
We measured the six tumor markers, CA125, TPA, Fr, CEA, AFP, and PPA simultaneously in serodiagnostic testing as a method for the early detection of ovarian cancer. To decrease the false negativity in the combination assay, statistical discriminating analysis was applied to serum values for tumor markers. "The ovarian cancer screening test" designed by us has been enforced in Shizuoka Prefecture since September, 1985. Twenty-one thousand nine hundred serum samples had been analysed by December, 1988. Eighty-four cases out of the 125 patients with ovarian cancer were suspected of being malignant pretherapeutically in a clinical diagnostic procedure which included echography. On the other hand, malignancy was justified before treatment in 109 patients in the combination assay and statistical analysis. One hundred patients were diagnosed as malignant in the combination assay and 9 cases by statistical analysis. However, we overlooked 4 patients (3 patients were found to be in stage I and one in stage III, respectively) even when both methods were used. Altogether 37 more patients with ovarian cancer could be found by the serodiagnostic screening method with discriminating analysis using tumor markers than by clinical findings such as image diagnosis and others. To conclude, the discriminating analysis was, therefore, verified as a useful technique for the diagnosis of ovarian cancer.
Kobayashi
H
H
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine.
Sumimoto
K
K
Terao
T
T
Kawashima
Y
Y
Kouda
M
M
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002986:Clinical Trials as Topic; D016002:Discriminant Analysis; D005188:False Negative Reactions; D005260:Female; D005293:Ferritins / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000276:immunology; D010455:Peptides / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000097:blood; D019396:Tissue Polypeptide Antigen; D000509:alpha-Fetoproteins / Q000032:analysis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010455:Peptides; D019396:Tissue Polypeptide Antigen; D000509:alpha-Fetoproteins; D005293:Ferritins; D010959:Tissue Plasminogen Activator